Disease · MONDO_0010604
Trials54
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 13 more are not shown, since the checks do not confirm them.
1 to 20 of 54
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01154231 | BeneFIX Drug Use Results Survey [All-Case Surveillance] | 314 | 2017-04-11 | Hemophilia B | COAGULATION FACTOR IX RECOMBINANT HUMAN | Its record names the disease | ClinicalTrials.gov | |
| NCT00484185 | Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B | 183 | 2013-08-12 | Hemophilia B | COAGULATION FACTOR IX RECOMBINANT HUMAN | Its record names the disease | ClinicalTrials.gov | |
| NCT01027364 | Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B | Phase 3 | 123 | 2014-09-04 | Severe Hemophilia B | COAGULATION FACTOR IX RECOMBINANT HUMAN, EFTRENONACOG ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT03417245 | A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors | Phase 3 | 120 | 2022-02-04 | Hemophilia A, Hemophilia B | FITUSIRAN | Its record names the disease | ClinicalTrials.gov |
| NCT01174446 | Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients | Phase 3 | 86 | 2013-11-25 | Hemophilia B | COAGULATION FACTOR IX RECOMBINANT HUMAN | Its record names the disease | ClinicalTrials.gov |
| NCT03549871 | A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis | Phase 3 | 80 | 2023-02-06 | Hemophilia | FITUSIRAN | Its record names the disease | ClinicalTrials.gov |
| NCT00768287 | Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B | Phase 2/3 | 77 | 2018-09-10 | Hemophilia B | COAGULATION FACTOR IX RECOMBINANT HUMAN | Its record names the disease | ClinicalTrials.gov |
| NCT01333111 | Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients | Phase 3 | 74 | 2017-07-28 | Congenital Bleeding Disorder, Haemophilia B | NONACOG BETA PEGOL | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT01395810 | Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773 | Phase 3 | 71 | 2018-05-09 | Congenital Bleeding Disorder, Haemophilia B | NONACOG BETA PEGOL | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT02336178 | Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China | Phase 4 | 70 | 2017-05-04 | HEMOPHILIA B | COAGULATION FACTOR IX RECOMBINANT HUMAN | Its record names the disease | ClinicalTrials.gov |
| NCT03569891 | HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients | Phase 3 | 67 | 2022-10-10 | Hemophilia B | ETRANACOGENE DEZAPARVOVEC | Its record names the disease | ClinicalTrials.gov |
| NCT03417102 | A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors | Phase 3 | 60 | 2021-12-21 | Hemophilia A, Hemophilia B | FITUSIRAN | Its record names the disease | ClinicalTrials.gov |
| NCT02141074 | Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B | Phase 3 | 54 | 2023-12-29 | Congenital Bleeding Disorder, Haemophilia B | NONACOG BETA PEGOL | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03861273 | A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B | Phase 3 | 51 | 2024-03-27 | Hemophilia B | FIDANACOGENE ELAPARVOVEC | Its record names the disease | ClinicalTrials.gov |
| NCT01757405 | Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen | Phase 3 | 40 | 2016-10-25 | Hemophilia A, Hemophilia B | EPTACOG ALFA (ACTIVATED) | Its record names the disease | ClinicalTrials.gov |
| NCT00866606 | Study Evaluating On-Demand Treatment With BeneFIX In Chinese Subjects | Phase 3 | 35 | 2011-01-04 | Hemophilia B | COAGULATION FACTOR IX RECOMBINANT HUMAN | Its record names the disease | ClinicalTrials.gov |
| NCT02554773 | An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B | Phase 1/2 | 34 | 2024-06-05 | Hemophilia A, Hemophilia B | FITUSIRAN | Its record names the disease | ClinicalTrials.gov |
| NCT02234310 | Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B | Phase 3 | 33 | 2020-07-31 | Hemophilia B | EFTRENONACOG ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT01440946 | Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B | Phase 3 | 30 | 2015-06-18 | Hemophilia B | EFTRENONACOG ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT01507896 | BAX 326 Surgery Study in Hemophilia B Patients | Phase 3 | 30 | 2017-02-15 | Hemophilia B | COAGULATION FACTOR IX RECOMBINANT HUMAN | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0010604/trials